|
US6972193B1
(en)
*
|
1993-02-12 |
2005-12-06 |
Board Of Trustees Of Leland Stanford Junior University |
Regulated transcription of targeted genes and other biological events
|
|
US6891021B2
(en)
*
|
1993-02-12 |
2005-05-10 |
Board Of Trustees Of The Leland Stanford Junior University |
Regulated apoptosis
|
|
JP2002544285A
(ja)
*
|
1999-05-14 |
2002-12-24 |
メディカル リサーチ カウンシル |
オリゴマーシャペロンタンパク質
|
|
WO2000069907A1
(en)
*
|
1999-05-14 |
2000-11-23 |
Medical Research Council |
Protein scaffold and its use to multimerise monomeric polypeptides
|
|
WO2000071743A1
(fr)
*
|
1999-05-25 |
2000-11-30 |
Eisai Co., Ltd. |
Methode bihybride dans une cellule de mammifere
|
|
US6537540B1
(en)
*
|
1999-05-28 |
2003-03-25 |
Targeted Genetics Corporation |
Methods and composition for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders
|
|
EP1181360A1
(en)
*
|
1999-05-28 |
2002-02-27 |
Sangamo Biosciences Inc. |
Molecular switches
|
|
US7057015B1
(en)
|
1999-10-20 |
2006-06-06 |
The Salk Institute For Biological Studies |
Hormone receptor functional dimers and methods of their use
|
|
AU3642601A
(en)
*
|
1999-11-05 |
2001-05-30 |
Avigen, Inc. |
Ecdysone-inducible adeno-associated virus expression vectors
|
|
EP1254179A4
(en)
|
2000-01-24 |
2005-06-01 |
Univ Columbia |
IN VIVO SCREEN USING CHEMICAL INDUCTORS
|
|
US20040033600A1
(en)
|
2001-03-21 |
2004-02-19 |
Palli Subba Reddy |
Ecdysone receptor-based inducible gene expression system
|
|
WO2001070816A2
(en)
*
|
2000-03-22 |
2001-09-27 |
Rohm And Haas Company |
Ecdysone receptor-based inducible gene expression system
|
|
IL152871A0
(en)
*
|
2000-06-16 |
2003-06-24 |
Ariad Gene Therapeutics Inc |
Chimeric hsf transcription factors
|
|
EP1908835A3
(en)
*
|
2000-07-18 |
2008-06-18 |
Novartis AG |
Regulation of gene expression using single-chain, monomeric, ligand dependent polypeptide switches
|
|
US7011972B2
(en)
|
2000-07-18 |
2006-03-14 |
The Scripps Research Institute |
Fusion polypeptide comprising two ligand binding domains
|
|
IL154059A0
(en)
*
|
2000-07-21 |
2003-07-31 |
Syngenta Participations Ag |
Zinc finger domain recognition code and uses thereof
|
|
US8105825B2
(en)
|
2000-10-03 |
2012-01-31 |
Intrexon Corporation |
Multiple inducible gene regulation system
|
|
US6576422B1
(en)
*
|
2000-10-17 |
2003-06-10 |
Rohm And Haas Company |
Method for identifying products employing gene expression
|
|
ES2385598T3
(es)
|
2001-02-20 |
2012-07-27 |
Intrexon Corporation |
Sistema novedoso de expresión génica inducible basado en el receptor de ecdisona/receptor X retinoide de invertebrado
|
|
EP1534738B1
(en)
|
2001-02-20 |
2012-06-20 |
Intrexon Corporation |
Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
|
|
CA2438119C
(en)
|
2001-02-20 |
2014-12-16 |
Rheogene Holdings, Inc. |
Chimeric retinoid x receptors and their use in a novel ecdysone receptor-based inducible gene expression system
|
|
AU2002306550B2
(en)
|
2001-02-20 |
2007-10-25 |
Intrexon Corporation |
Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
|
|
ATE497603T1
(de)
|
2001-03-02 |
2011-02-15 |
Gpc Biotech Ag |
Drei-hybrid-assaysystem
|
|
US20040224385A1
(en)
*
|
2001-08-20 |
2004-11-11 |
Barbas Carlos F |
Zinc finger binding domains for cnn
|
|
US6858429B2
(en)
*
|
2001-08-23 |
2005-02-22 |
The Regents Of The University Of California |
Universal light-switchable gene promoter system
|
|
WO2003020906A2
(en)
*
|
2001-08-31 |
2003-03-13 |
Abmaxis, Inc. |
Multivalent protein conjugate with multiple ligand-binding domains of receptors
|
|
JP2005532781A
(ja)
|
2001-09-26 |
2005-11-04 |
レオジーン・ホールディングス，インコーポレーテッド |
ヨコバイエクジソン受容体核酸、ポリペプチド、およびそれらの使用
|
|
CA2462598A1
(en)
*
|
2001-10-01 |
2003-04-10 |
Bioimage A/S |
A method of detecting intracellular protein-protein interactions using three heterologous conjugates
|
|
US8765408B2
(en)
|
2002-01-23 |
2014-07-01 |
Wisconsin Alumni Research Foundation |
Prophage element-free bacteria
|
|
US20060270043A1
(en)
*
|
2002-01-23 |
2006-11-30 |
Blattner Frederick R |
Bacteria with reduced genome
|
|
US8119365B2
(en)
*
|
2002-01-23 |
2012-02-21 |
Wisconsin Alumni Research Foundation |
Insertion sequence-free bacteria
|
|
US6989265B2
(en)
*
|
2002-01-23 |
2006-01-24 |
Wisconsin Alumni Research Foundation |
Bacteria with reduced genome
|
|
US8039243B2
(en)
*
|
2002-01-23 |
2011-10-18 |
Wisconsin Alumni Research Foundation |
Insertion sequence-free bacteria
|
|
EP1478648B1
(en)
|
2002-02-01 |
2014-04-30 |
ARIAD Pharmaceuticals, Inc. |
Phosphorus-containing compounds and uses thereof
|
|
US6845929B2
(en)
*
|
2002-03-22 |
2005-01-25 |
Ali Dolatabadi |
High efficiency nozzle for thermal spray of high quality, low oxide content coatings
|
|
US7083918B2
(en)
|
2002-04-24 |
2006-08-01 |
The Trustees Of Columbia University In The City Of New York |
Bacterial small-molecule three-hybrid system
|
|
CA2485939C
(en)
*
|
2002-05-29 |
2013-10-29 |
Regeneron Pharmaceuticals, Inc. |
Inducible eukaryotic expression system
|
|
US8673589B2
(en)
|
2002-05-29 |
2014-03-18 |
Regeneron Pharmaceuticals, Inc. |
Inducible eukaryotic expression system
|
|
US7303906B2
(en)
*
|
2002-09-06 |
2007-12-04 |
Wisconsin Alumni Research Foundation |
Competent bacteria
|
|
EP1563298A4
(en)
*
|
2002-11-05 |
2006-12-20 |
Regeneron Pharma |
METHODS OF ISOLATING ACTIVE COMPOUNDS AND ACTIVATED TARGETS
|
|
US7385027B2
(en)
*
|
2003-01-07 |
2008-06-10 |
University Of Kentucky Research Foundation |
Membrane-permeable peptide capable of calpain inhibition
|
|
US7304161B2
(en)
|
2003-02-10 |
2007-12-04 |
Intrexon Corporation |
Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex
|
|
US7456315B2
(en)
|
2003-02-28 |
2008-11-25 |
Intrexon Corporation |
Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
|
|
US20050136035A1
(en)
*
|
2003-06-03 |
2005-06-23 |
Derek Ko |
Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
|
|
WO2005017149A1
(en)
*
|
2003-06-03 |
2005-02-24 |
Cell Genesys, Inc. |
Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
|
|
US7935510B2
(en)
|
2004-04-30 |
2011-05-03 |
Intrexon Corporation |
Mutant receptors and their use in a nuclear receptor-based inducible gene expression system
|
|
EP1765846A4
(en)
*
|
2004-07-13 |
2010-02-17 |
Cell Genesys Inc |
AAV VECTOR COMPOSITIONS AND ITS USE IN PROCESSES FOR INCREASING IMMUNOGLOBULIN EXPRESSION
|
|
US7632509B2
(en)
|
2005-07-19 |
2009-12-15 |
Biosante Pharmaceuticals, Inc. |
Methods to express recombinant proteins from lentiviral vectors
|
|
US20070292922A1
(en)
*
|
2006-03-31 |
2007-12-20 |
Cell Genesys, Inc. |
Regulated expression of recombinant proteins from adeno-associated viral vectors
|
|
US20090136465A1
(en)
|
2007-09-28 |
2009-05-28 |
Intrexon Corporation |
Therapeutic Gene-Switch Constructs and Bioreactors for the Expression of Biotherapeutic Molecules, and Uses Thereof
|
|
EP2550359B1
(en)
|
2010-03-23 |
2017-08-09 |
Intrexon Corporation |
Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof
|
|
WO2011126808A2
(en)
|
2010-03-29 |
2011-10-13 |
The Trustees Of The University Of Pennsylvania |
Pharmacologically induced transgene ablation system
|
|
US9315825B2
(en)
|
2010-03-29 |
2016-04-19 |
The Trustees Of The University Of Pennsylvania |
Pharmacologically induced transgene ablation system
|
|
EP2681327B1
(en)
|
2011-03-04 |
2018-11-21 |
Intrexon Corporation |
Vectors conditionally expressing protein
|
|
EP3699286A1
(en)
|
2011-04-20 |
2020-08-26 |
The Trustees of the University of Pennsylvania |
Regimens and compositions for aav-mediated passive immunization of airborne pathogens
|
|
US10246503B2
(en)
*
|
2012-12-24 |
2019-04-02 |
Beijing Anxinhuaide Biotech. Co., Ltd. |
Method of improving the pharmacokinetic profile of a therapeutic polypeptide and the use thereof
|
|
ES2683329T3
(es)
|
2013-03-15 |
2018-09-26 |
Intrexon Corporation |
Diacilhidrazinas que contienen boro
|
|
US9719106B2
(en)
|
2013-04-29 |
2017-08-01 |
The Trustees Of The University Of Pennsylvania |
Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
|
|
EP3613854A1
(en)
*
|
2014-03-05 |
2020-02-26 |
National University Corporation Kobe University |
Genomic sequence modification method for specifically converting nucleic acid bases of targeted dna sequence, and molecular complex for use in same
|
|
EP3194359B1
(en)
|
2014-09-17 |
2020-04-08 |
Intrexon Corporation |
Boron-containing diacylhydrazine compounds
|
|
JP6153180B2
(ja)
*
|
2014-11-04 |
2017-06-28 |
国立大学法人神戸大学 |
脱塩基反応により標的化したｄｎａ配列に特異的に変異を導入する、ゲノム配列の改変方法、並びにそれに用いる分子複合体
|
|
WO2016200543A2
(en)
|
2015-05-13 |
2016-12-15 |
The Trustees Of The University Of Pennsylvania |
Aav-mediated expression of anti-inluenza antibodies and methods of use thereof
|
|
AU2016334401A1
(en)
|
2015-10-10 |
2018-04-26 |
Intrexon Corporation |
Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12
|
|
US20180230489A1
(en)
|
2015-10-28 |
2018-08-16 |
Voyager Therapeutics, Inc. |
Regulatable expression using adeno-associated virus (aav)
|
|
CN108495932B
(zh)
|
2015-11-27 |
2022-08-09 |
国立大学法人神户大学 |
用于特异性转换靶向dna序列的核酸碱基的单子叶植物的基因组序列的转换方法、及其使用的分子复合体
|
|
IL262207B2
(en)
|
2016-04-15 |
2026-01-01 |
Univ Pennsylvania |
Preparations for the treatment of wet age-related macular degeneration
|
|
UY37343A
(es)
|
2016-07-25 |
2018-02-28 |
Intrexon Corp |
Control del fenotipo en plantas
|
|
AU2017359342B2
(en)
|
2016-11-09 |
2022-02-17 |
Intrexon Corporation |
Frataxin expression constructs
|
|
RS65241B1
(sr)
|
2017-02-28 |
2024-03-29 |
Univ Pennsylvania |
Vektor adeno-asociranih virusa (aav) iz podgrupe f i njegove upotrebe
|
|
JOP20190200A1
(ar)
|
2017-02-28 |
2019-08-27 |
Univ Pennsylvania |
تركيبات نافعة في معالجة ضمور العضل النخاعي
|
|
TW201837170A
(zh)
|
2017-02-28 |
2018-10-16 |
賓州大學委員會 |
新穎ａａｖ媒介的流感疫苗
|
|
KR20200067195A
(ko)
|
2017-10-18 |
2020-06-11 |
리젠엑스바이오 인크. |
완전-인간 번역후 변형된 항체 치료제
|
|
MX2020003945A
(es)
|
2017-10-18 |
2020-11-09 |
Regenxbio Inc |
Tratamiento de enfermedades oculares y cancer de colon metastasico con vegf-trap humano modificado post-traduccionalmente .
|
|
US12558434B2
(en)
|
2018-02-20 |
2026-02-24 |
The Trustees Of The University Of Pennsylvania |
Compositions for treatment of wet age-related macular degeneration
|
|
EP4667578A3
(en)
|
2019-04-03 |
2026-04-01 |
REGENXBIO Inc. |
Gene therapy for eye pathologies
|
|
US20220195462A1
(en)
|
2019-04-24 |
2022-06-23 |
Regenxbio Inc. |
Fully-human post-translationally modified antibody therapeutics
|
|
CA3149401A1
(en)
|
2019-08-26 |
2021-03-04 |
Stephen Joseph Pakola |
Treatment of diabetic retinopathy with fully-human post-translationally modified anti-vegf fab
|
|
WO2021071835A1
(en)
|
2019-10-07 |
2021-04-15 |
Regenxbio Inc. |
Adeno-associated virus vector pharmaceutical composition and methods
|
|
US20250326861A1
(en)
|
2020-09-15 |
2025-10-23 |
Regenxbio Inc. |
Vectorized lanadelumab and administration thereof
|
|
EP4214242A1
(en)
|
2020-09-15 |
2023-07-26 |
RegenxBio Inc. |
Vectorized antibodies for anti-viral therapy
|
|
JP2023544803A
(ja)
|
2020-10-07 |
2023-10-25 |
レジェンクスバイオ インコーポレーテッド |
Ｃｌｎ２疾患の眼症状に対する遺伝子療法
|
|
WO2022094157A1
(en)
|
2020-10-28 |
2022-05-05 |
Regenxbio Inc. |
Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereof
|
|
AU2021371307A1
(en)
|
2020-10-28 |
2023-06-01 |
Regenxbio, Inc. |
VECTORIZED ANTI-TNF-α ANTIBODIES FOR OCULAR INDICATIONS
|
|
KR20230098176A
(ko)
|
2020-10-29 |
2023-07-03 |
리젠엑스바이오 인크. |
안구 적응증을 위한 벡터화된 tnf-알파 길항제
|
|
US20230390418A1
(en)
|
2020-10-29 |
2023-12-07 |
Regenxbio Inc. |
Vectorized factor xii antibodies and administration thereof
|
|
AR124216A1
(es)
|
2020-12-01 |
2023-03-01 |
Univ Pennsylvania |
Composiciones nuevas con motivos selectivos específicos del tejido y composiciones que las contienen
|
|
AU2022262771A1
(en)
|
2021-04-23 |
2023-11-02 |
The Trustees Of The University Of Pennsylvania |
Novel compositions with brain-specific targeting motifs and compositions containing same
|
|
US20240384298A1
(en)
|
2021-10-02 |
2024-11-21 |
The Trustees Of The University Of Pennsylvania |
Novel aav capsids and compositions containing same
|
|
CN119317718A
(zh)
|
2022-01-25 |
2025-01-14 |
宾夕法尼亚州大学信托人 |
用于改善心脏转导和肝脏去靶向的aav衣壳
|
|
US20250249127A1
(en)
|
2022-04-14 |
2025-08-07 |
Regenxbio Inc. |
Gene therapy for treating an ocular disease
|
|
WO2023205610A2
(en)
|
2022-04-18 |
2023-10-26 |
Regenxbio Inc. |
Hybrid aav capsids
|
|
TW202417633A
(zh)
|
2022-05-03 |
2024-05-01 |
美商銳進科斯生物股份有限公司 |
用於眼適應症之載體化抗TNF-α抑制劑
|
|
TW202400803A
(zh)
|
2022-05-03 |
2024-01-01 |
美商銳進科斯生物股份有限公司 |
載體化抗補體抗體與補體劑及其投與
|
|
EP4593955A1
(en)
|
2022-09-30 |
2025-08-06 |
RegenxBio Inc. |
Treatment of ocular diseases with recombinant viral vectors encoding anti-vegf fab
|
|
EP4634394A2
(en)
|
2022-12-17 |
2025-10-22 |
The Trustees of The University of Pennsylvania |
Recombinant aav mutant vectors with cardiac and skeletal muscle-specific targeting motifs and compositions containing same
|
|
WO2024130070A2
(en)
|
2022-12-17 |
2024-06-20 |
The Trustees Of The University Of Pennsylvania |
Recombinant aav capsids with cardiac- and skeletal muscle- specific targeting motifs and uses thereof
|
|
WO2024238867A1
(en)
|
2023-05-16 |
2024-11-21 |
Regenxbio Inc. |
Vectorized anti-complement antibodies and administration thereof
|
|
WO2024238859A1
(en)
|
2023-05-16 |
2024-11-21 |
Regenxbio Inc. |
Vectorized c5 inhibitor agents and administration thereof
|
|
WO2025007046A1
(en)
|
2023-06-29 |
2025-01-02 |
The Trustees Of The University Of Pennsylvania |
Mutant aav with central nervous system targeting motifs and compositions containing same
|
|
WO2025102034A1
(en)
|
2023-11-10 |
2025-05-15 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for barth syndrome
|
|
KR20260114566A
(ko)
|
2023-11-14 |
2026-07-22 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
심근 및 골격근-특이적 표적화 모티프를 갖는 조성물 및 이의 용도
|
|
WO2025217230A1
(en)
|
2024-04-08 |
2025-10-16 |
Regenxbio Inc. |
Vectorized anti-complement antibodies and complement agents and administration thereof
|
|
WO2026122921A1
(en)
|
2024-12-05 |
2026-06-11 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for barth syndrome
|